AbbVie ABBV remains a dominant force in the immunology space, powered by the continued uptake of its two blockbuster medications, Skyrizi and Rinvoq. The robust demand for both drugs has helped the ...

Oct 31 (Reuters) - AbbVie (ABBV.N), opens new tab said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, which in 2024 yielded discounts ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

PARIS, Oct 9 (Reuters) - After falling short of a majority in last year's snap legislative vote, French far-right leader Marine Le Pen said her party's victory had merely been delayed. Fifteen months ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) – UC and ...

PARIS — Marine Le Pen has already helped topple two French governments in less than a year. She didn’t even need to pull the trigger to kill off a third one. The far-right leader was bullish on Monday ...

France's government collapsed Monday after the country's Prime Minister Sébastien Lecornu tendered his resignation less than a day after appointing his cabinet. The resignation of the country's second ...

Aston Villa boss Unai Emery said his side have to become more clinical from the penalty spot after a shock Europa League defeat to Dutch minnows Go Ahead Eagles. Emiliano Buendía missed a late ...

AstraZeneca has signed a $555 million deal with San Francisco biotech Algen Biotechnologies that will tap the latter company’s artificial intelligence platform to boost discovery of new targets in ...

Just days after the “No Kings” protests against President Donald Trump, the city and county of San Diego took action to further restrict local agencies from assisting federal agents on immigration ...

Thanks to new settlement agreements with three generic drug makers, Gilead Sciences has extended the expected life span of its flagship HIV treatment Biktarvy by as many years. Gilead has struck ...

Only four bottles of Asahi Super Dry beer are left on the shelves of Ben Thai, a cosy restaurant in the Tokyo suburb of Sengawacho. Its owner, Sakaolath Sugizaki, expects to get a few more soon, but ...